CA125对Her-2阳性乳腺癌患者术后生物化疗疗效的评估价值  

Role of serum tumor marker CA125 in predicting response during biochemotherapy after surgery in Her-2-positive breast cancer

作　　者：陈晓华 曹小龙 陈逢生[2] 陈旭坚[2] 罗荣城[2] 

机构地区：[1]广州市番禺区中心医院肿瘤科,广州511400 [2]广州南方医科大学附属南方医院肿瘤中心,广州510515

出　　处：《癌症进展》2014年第5期469-478,共10页Oncology Progress

基　　金：广东省自然科学基金(S2011040000786);番禺区科技计划项目(2013-专15-6.10)

摘　　要：目的探讨血清糖类抗原125(CA125)在Her-2阳性乳腺癌患者术后生物化疗疗效监测的评估价值。方法回顾性分析以蒽环类及紫杉类为基础联合曲妥珠单抗﹙Herceptin﹚治疗44例Her-2阳性乳腺癌患者术后血清CA125的变化。根据2000年实体瘤疗效评价标准(RECIST)标准分有效组(OR组)及无效组(NR组),通过分析两组治疗前后CA125的变化及下降比率绘制ROC曲线评估其对生物化疗疗效的价值。结果与治疗前相比,所有患者治疗后CA125血清水平显著下降(P<0.05)。治疗前有效组及无效组间CA125无明显差异(P>0.05);治疗后有效组血清CA125水平显著下降(P<0.05),而无效组治疗前后无显著性差异(P>0.05)。采用治疗前后CA125下降比率绘制ROC曲线,其曲线下面积为0.701。结论CA125在Her-2阳性乳腺癌患者术后生物化疗疗效有一定预测作用,且有较高的敏感性及特异性。Objective To evaluate the role of CA125 in predicting response during biochemotherapy after surgery in Her-2 positive breast cancer patients. Method CA125 level changes in 44 cases of Her-2 positive breastcancer during biochemotherapy（base on paclitaxel or anthraceneand with Herceptin） after surgery were analyzed retrospectively. All patients were divided into responsive group（OR group） or unresponsive group（NR group） according to RECIST criteria of the year of 2000. ROC curve was plotted based on the decrease rate of CA125 to evaluate its role in predicting response. Result CA125 level decreased significantly in all patients and in the OR group after biochemotherapy（P〈0.05）, while it showed no significant differences in OR vs NR group before biochemotherapy（P〉0.05）, as well as in the NR group before vs after biochemotherapy（P〉0.05）. AUC of CA125 was 0.701. Conclusion CA125 may predict the response in Her-2 positive breast cancer during biochemotherapy, with superior specificity and sensitivity.

关 键 词：乳腺癌 生物化疗 CA125 疗效评估 

分 类 号：R737.9[医药卫生—肿瘤]